Answers are grounded in this paper and cite their sources.
The authors describe a novel multifunctional magneto-fluorescent MFCSNPs-FA-CHI-5FU nanocarrier that consists of magneto-fluorescent nanoparticles (MFCSNPs) targeted with folic acid (FA), modified with chitosan (CHI), and loaded with a 5-flouoruracil (5-FU) in dual mode imaging and targeted drug delivery. Multifunctional magneto-fluorescent nanocarriers show multicolor emission and superparamagnetic behavior which are advantageous for bioimaging and magnetic resonance (MR) imaging, respectively. In-vitro drug release studies show a pH-activated drug release with 92% of loaded 5-FU released in 30 h and MR imaging exhibiting excellent dose-dependent signal enhancement in T 2 -weighted images. This suggests that MFCSNPs-FA-CHI-5FU nanocarriers can be used as T 2 -weighted negative contrast agents in cancer diagnosis. In-vitro cytotoxicity and anticancer activity of the synthesized MFCSNPs-FA-CHI-5FU nanocarriers were evaluated on three cancer cell lines having different percentages of folate receptors viz. A375, MCF-7, and HeLa cells. The results show a very sensitive drug targeting response. Confocal laser scanning microscopy imaging (CLSM) displays targeted cellular internalization of MFCSNPs-FA-CHI-5FU nanocarriers in cancer cells. The biocompatibility of MFCSNPs-FA-CHI-5FU nanocarriers was ascertained ex-vivo by hemolysis and serum stability studies. The in vivo biodistribution studies were evaluated by radiolabeling MFCSNPs-FA-CHI-5FU nanocarriers with 99m technetium ( 99m Tc). Thus, the synthesized nanocarriers, a dual mode imaging probe, show great potential in targeted drug delivery to improve the existing cancer theranostics.
No takes yet. Share an insight, caveat, or question.
Tiwari et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: